Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ABAX

Abaxis (ABAX) Stock Price, News & Analysis

Abaxis logo

About Abaxis Stock (NASDAQ:ABAX)

Key Stats

Today's Range
$83.00
$83.00
50-Day Range
N/A
52-Week Range
$43.66
$83.98
Volume
N/A
Average Volume
167,754 shs
Market Capitalization
N/A
P/E Ratio
42.35
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results; VetScan UA, a urinalysis solution; and VetScan SA, which is designed to perform urine microscopy. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.

Receive ABAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abaxis and its competitors with MarketBeat's FREE daily newsletter.

ABAX Stock News Headlines

AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
See More Headlines

ABAX Stock Analysis - Frequently Asked Questions

Abaxis, Inc. (NASDAQ:ABAX) posted its quarterly earnings data on Thursday, April, 26th. The medical research company reported $0.42 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.10. The business's quarterly revenue was up 16.7% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abaxis investors own include Skyworks Solutions (SWKS), Wells Fargo & Company (WFC), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Allergan (AGN), Akorn (AKRX) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
4/26/2018
Today
12/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Measuring & Controlling Devices
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ABAX
CUSIP
00256710
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ABAX) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners